Several chronic studies in rats indicating that cadmium exposure can induce tumors of the ventral prostate have recently been completed in our laboratory. In one such study, a single dose of cadmium, s.c., increased prostatic tumor incidence only at doses below 5.0 pmol/kg, the approximate threshold for cadmium-induced testicular damage. In a further study, prostatic tumors were elevated with higher doses of cadmium (30 pmol/kg, s.c.) if testicular damage was prevented by zinc pretreatment. Most recently, we found that dietary cadmium (25 to 200 pg/g) also can increase prostatic neoplastic lesions, but these were reduced by zinc-deficient diets. Thus it appears that cadmium produces prostatic tumors only if testicular function is maintained. Furthermore, we find that metallothionein (MT), a protein associated with cadmium tolerance, may be deficient in the rat prostate, and the prostatic MT gene, at least in the ventral lobe, is unresponsive to metal stimuli. In liver, MT gene expression, as assessed by MT-I mRNA, was quite apparent in control tissue and was induced in a dose-dependent manner 24 hr following cadmium exposure (1 to 10 pmol/kg, s.c.). However, in the ventral prostate very low constitutive levels of MT-I mRNA were detected and increases did not occur with cadmium exposure. Cadmium concentrations in the ventral prostate were in excess of those that cause significant induction in the liver. In sharp contrast to the gene in the ventral prostate, in the dorsal prostate the MT gene was quite active. The dorsal prostate is not susceptible to cadmium carcinogenesis. The association between tissue-specific quiescence of the MT gene and susceptibility to cadmium carcinogenesis deserves further study.
Introduction
Cadmium is a highly toxic metal that is cause for elevated environmental and occupational concern due to increasing exposure of humans. In animal models, cadmium is a potent carcinogen that is capable of inducing a variety of tumors (for review see 1); both the lung (2) and more recently the prostate (3) (4) (5) have been identified as target sites for cadmium-induced tumors. In humans, cadmium is classified by the IARC as a suspected human carcinogen (Group 2A) with the lung and possibly the prostate as target organs (6, 7) .
The exact mechanism of cadmium carcinogenesis is unknown. However, the level of metallothionein (MT) gene expression may play a role in determining a tissues's susceptibility to cadmium-induced tumors.
MT is a low molecular weight (6000 to 7000 daltons) metal binding protein, the amino acid content of which is approximately 30% cysteine residues (8) . This high content of cysteinyl thiol groups accounts for the high metal affinity of MT (8) . Although MT is found in a variety of eukaryotic cells, its physiologic functions are still unknown. However, MT appears to function, in part, in cellular defenses against metal toxicity (9) . In particular, MT appears to play an important role in providing protection from cadmium toxicity. It is possible that reduced levels of MT gene expression may lead to an increase in a tissue's susceptibility to cadmium carcinogenesis.
A number of studies from our laboratory have demonstrated that the rat ventral prostate is a target site for cadmiuminduced tumors. (3) (4) (5) . The following will summarize these studies, as well as provide new data with regard to MT gene expression in this target for cadmium carcinogenicity.
In the first study, male Wistar [Crl:(WI)BR) rats were given a single s.c. dose of cadmium (0, 1, 2.5, 5, 10, 20, or 40 pmole/kg) and studied over a 2 year period (3) . A strong positive correlation was established between the dose of cadmium and the incidence and multiplicity of prostatic tumors for doses up to 2.5 pimole/kg. A significant increase in prostatic tumor incidence was These chronic studies in rats establish that the rat ventral prostate is a target for cadmium-induced tumors. Hyperplastic lesions were evident at high doses of cadmium in the absence of an increase in prostatic tumors (3), and the lack of increased prostatic tumor formation at higher doses parallels a loss of testicular function. These studies demonstrate the importance of testicular function in the development, but not initiation, of prostatic tumors.
Since MT is thought to provide protection against the toxic effects of cadmium, we hypothesized that the increased susceptibility to cadmium carcinogenicity demonstrated for the ventral prostate may be due to alterations in MT gene expression. One possible pathway for cadmium carcinogenicity may involve the interaction of cadmium with DNA, either directly or indirectly. Previous studies in our laboratory have shown that an increase in MT gene expression can reduce the level of DNA damage associated with cadmium exposure (10) . Hence, a deficiency of MT may contribute to a tissue's susceptiblity to cadmium carcinogenicity. Therefore, we investigated MT production and gene expression in the ventral prostate as well as in the dorsolateral prostate and liver, two tissues that are not targets for cadmium carcinogenicity in the rat.
Metallothionein levels were determined using the Onosaka assay (11) as modified by Eaton and Toal (12) . Basal the dorsolateral prostate were significantly higher than those of either the liver or ventral prostate. In addition, liver MT levels were greater than that of the ventral prostate. In general, MT levels correlated with zinc tissue levels for the tissues examined. The dorsolateral prostate had the greatest zinc content and in turn, the highest MT levels. Although the liver and ventral prostate were not significantly different in zinc content, the liver did contain significantly greater basal MT levels. Ventral prostate contained very low basal levels of MT, almost at the limit of detection with this assay (12) .
Analysis of MT mRNA from each tissue correlated with the data obtained from the MT protein assay (Figure 1 ). Total RNA was isolated using RNAzol, denatured with glyoxal and slot-blotted onto Nytran, as previously described (10) . RNA integrity was determined by electrophoresis and message size confirmed by northern analysis. Northern transfers and slot-blots were probed for MT-I gene expression using a 32P-labeled p2A10 plasmid for the MT-I gene generously supplied by Dr. H. Herschman (13) . RNA loading was standardized to 3-actin gene expression. MT-I gene expression was greatest in the dorsolateral prostate and was very low in the ventral prostate. Similar data were obtained with probes specific for MT-II RNA.
The ability of cadmium to induce MT was investigated in the liver and ventral prostate. MT levels are presented in Table  2 . Animals were exposed to cadmium s.c. and MT levels were assessed at 24 hr. 
